US population qualifying for aspirin use for primary prevention of cardiovascular disease

•7 % of US adults 40–59 years are eligible for primary prevention aspirin by USPSTF.•Higher proportional eligibility among men, older age (50–59 years), Black race.•30 % of individuals potentially eligible meet increased bleeding risk criteria.•Limited role of primary prevention aspirin in modern era under USPSTF guidelines.